| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.75B | 9.38B | 9.20B | 10.54B | 10.48B |
| Gross Profit | 1.84B | 2.29B | 2.06B | 2.06B | 2.52B |
| EBITDA | 1.29B | 1.80B | 1.81B | 1.64B | 1.81B |
| Net Income | 474.00M | 905.00M | 894.00M | 793.00M | 857.00M |
Balance Sheet | |||||
| Total Assets | 14.86B | 15.21B | 14.63B | 14.67B | 15.52B |
| Cash, Cash Equivalents and Short-Term Investments | 566.00M | 837.00M | 548.00M | 493.00M | 459.00M |
| Total Debt | 5.08B | 5.26B | 5.14B | 5.15B | 5.52B |
| Total Liabilities | 8.82B | 9.36B | 9.10B | 9.43B | 9.73B |
| Stockholders Equity | 5.96B | 5.78B | 5.46B | 5.15B | 5.70B |
Cash Flow | |||||
| Free Cash Flow | 424.00M | 688.00M | 546.00M | 364.00M | 1.04B |
| Operating Cash Flow | 970.00M | 1.29B | 1.37B | 975.00M | 1.62B |
| Investing Cash Flow | -462.00M | -534.00M | -432.00M | 392.00M | -29.00M |
| Financing Cash Flow | -797.00M | -454.00M | -888.00M | -1.32B | -1.69B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $8.94B | 46.64 | 7.55% | 1.25% | 3.87% | -10.30% | |
68 Neutral | $8.80B | 18.81 | 8.07% | 5.33% | -3.33% | -19.59% | |
66 Neutral | $5.82B | 13.95 | 25.75% | 1.59% | -1.11% | 5.15% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | $22.02B | -34.03 | -5.24% | 1.10% | -23.92% | 90.47% | |
55 Neutral | $13.36B | -8.80 | -15.56% | 2.88% | -5.32% | -1108.29% | |
50 Neutral | $6.21B | -11.65 | -9.20% | ― | -3.59% | -126.16% |
On February 20, 2026, Eastman Chemical Company issued $600 million of 4.500% unsecured notes due 2031 in a public offering, with interest payable semi-annually and optional redemption features that allow early repayment under specified make-whole and par call terms. The notes, which rank equally with Eastman’s other unsecured, unsubordinated debt and include covenants limiting secured borrowing and certain transactions, also feature change-of-control protections that could trigger a repurchase at 101% of principal plus accrued interest.
The sale, underwritten by a syndicate led by major global banks, is expected to generate approximately $593.7 million in net proceeds after underwriting discounts and expenses. Eastman plans to use the funds for general corporate purposes, including working capital, capital expenditures, potential debt repayment and support of its strategic initiatives, reinforcing financial flexibility and funding capacity for ongoing operational and growth plans.
The most recent analyst rating on (EMN) stock is a Hold with a $75.00 price target. To see the full list of analyst forecasts on Eastman Chemical stock, see the EMN Stock Forecast page.